z-logo
open-access-imgOpen Access
Elizabethkingia meningosepticumin a Patient with Six-Year Bilateral Perma-Catheters
Author(s) -
Konstantin Boroda,
Li Li
Publication year - 2014
Publication title -
case reports in infectious diseases
Language(s) - English
Resource type - Journals
eISSN - 2090-6625
pISSN - 2090-6633
DOI - 10.1155/2014/985306
Subject(s) - medicine , levofloxacin , bacteremia , antibiotics , piperacillin , vancomycin , pneumonia , ceftazidime , tazobactam , blood culture , intensive care medicine , imipenem , antibiotic resistance , staphylococcus aureus , microbiology and biotechnology , pseudomonas aeruginosa , genetics , bacteria , biology
Elizabethkingia meningosepticum (EM) is a saprophyte which is ubiquitous in nature, but not normally present in the human flora. Instances of infection are rare in the USA, but EM may be an emerging pathogen among immune-compromised patients. EM can cause a variety of infections, but nosocomial pneumonia and bacteremia have been the most commonly reported among immune-compromised adults. EM has proven difficult to treat with a mortality rate of 23%–41% in adult bacteremia. This is likely due to its resistance to commonly used empiric antibiotics for Gram-negative infections. A review of the literature suggests that there has been a shift EM's susceptibility profile over time along with a great variability in antibiotic susceptibilities reported. This signifies the importance of close monitoring of these changes. In this report we present a case of a 64-year-old male with end stage renal disease and bilateral subclavian perma-catheters, who was admitted with systemic inflammatory response syndrome. While initial peripheral blood cultures were negative, cultures later drawn from his perma-catheters revealed Corneybacterium species and EM. The patient was initially treated with empiric vancomycin and piperacillin-tazobactam. After antibiotics susceptibilities became available, he was treated with levofloxacin and ceftazidime. The patient improved, was culture negative, and later had perma-catheter removal.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom